EyePoint Pharmaceuticals Advances Wet AMD Treatment with Phase 3 Trials
Key Insights
EyePoint Pharmaceuticals initiates the LUGANO Phase 3 study and prepares for the LUCIA study for wet AMD (search), marking progress in TKI (search)-based treatments.
The LUGANO and LUCIA trials will enroll both treatment-naive and treatment-experienced patients across 150 international sites, with data expected by mid-2026.
Analysts maintain positive ratings for EyePoint, with Jefferies projecting Duravyu could achieve peak adjusted sales of $600M in the U.S. and $500M in the EU.
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) is making significant strides in the development of its Duravyu treatment for wet Age-related Macular Degeneration (search) (AMD (search)) with the initiation of the global Phase 3 study, LUGANO, and preparations to begin its second pivotal study, LUCIA, by the end of the year. These trials represent a critical step in the competitive field of Tyrosine Kinase Inhibitor (TKI (search))-based long-acting treatments for wet AMD.
Clinical Trial Details
The LUGANO study has commenced patient enrollment across over 150 sites internationally. The LUCIA study is expected to begin by the end of the year. Both trials will enroll treatment-naive and treatment-experienced patients. Full patient enrollment for the trials is anticipated to take approximately nine to twelve months, with data readouts expected by mid-2026. This broad recruitment strategy is seen as a potential advantage for accelerating the enrollment process.
The studies' outcomes will provide crucial data on the efficacy and safety of the treatments being tested. These trials are designed to evaluate the effectiveness of Duravyu, EyePoint's investigational TKI (search)-based long-acting treatment, in patients with wet AMD (search).
Analyst Perspectives
CapitalOne reaffirmed its Underweight rating on EyePoint Pharmaceuticals stock with a price target of $35.00, acknowledging the commencement of the LUGANO study and the anticipated start of the LUCIA study as positive developments. Laidlaw has maintained its Buy rating and $50.00 price target on EyePoint Pharmaceuticals, expressing confidence in the company's potential. Jefferies initiated coverage on EyePoint Pharmaceuticals with a Buy rating, indicating a potential upside of over 65% and forecasts that Duravyu could achieve peak adjusted sales of $600 million in the U.S. and $500 million in the European Union, assuming a 100% focus on wAMD and a probability of success (PoS) of 65%.
Financial Health and Market Performance
EyePoint Pharmaceuticals' clinical progress is reflected in its financial metrics and market performance. The company's revenue growth stands at 34.98% for the last twelve months as of Q2 2024. EyePoint holds more cash than debt on its balance sheet, which is crucial for funding ongoing clinical trials like LUGANO and LUCIA. The company's stock has shown a strong return over the last year, with a 50.79% price total return, suggesting investor optimism about its pipeline potential.
Board Changes
EyePoint Pharmaceuticals has also made changes to its Board of Directors, welcoming industry veteran Fred Hassan, and announcing the resignations of Anthony P. Adamis, M.D. and David Guyer, M.D. due to their transition to full-time roles at Merck & Co.
These recent developments underscore EyePoint's commitment to addressing the challenges of serious retinal diseases. The ongoing Phase 3 clinical trials and potential FDA approval of Duravyu are key to the future of EyePoint Pharmaceuticals.